Norethisterone: Difference between revisions
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})) |
||
Line 10: | Line 10: | ||
== References == | == References == | ||
{{reflist}} | {{reflist|2}} | ||
{{Sex hormones}} | {{Sex hormones}} |
Revision as of 20:09, 4 September 2012
Clinical data | |
---|---|
Synonyms | (8R,9S,10R,13S,14S,17S)-17-ethynyl-17-hydroxy-13-methyl-1, 2,6,7,8,9,10,11,12,14,15, 16-dodecahydrocyclopenta[a]phenanthren-3-one |
ATC code | |
Pharmacokinetic data | |
Bioavailability | 64% |
Protein binding | >95% |
Elimination half-life | 7 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C20H26O2 |
Molar mass | 298.419 g/mol |
WikiDoc Resources for Norethisterone |
Articles |
---|
Most recent articles on Norethisterone Most cited articles on Norethisterone |
Media |
Powerpoint slides on Norethisterone |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Norethisterone at Clinical Trials.gov Trial results on Norethisterone Clinical Trials on Norethisterone at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Norethisterone NICE Guidance on Norethisterone
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Norethisterone Discussion groups on Norethisterone Patient Handouts on Norethisterone Directions to Hospitals Treating Norethisterone Risk calculators and risk factors for Norethisterone
|
Healthcare Provider Resources |
Causes & Risk Factors for Norethisterone |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Norethisterone (or norethindrone) (or 19-nor-17α-ethynyltestosterone) is a molecule used in some combined oral contraceptive pills and in some progestogen only pills. It is a progestogen and can be used to treat premenstrual syndrome, painful periods, abnormal heavy bleeding, irregular periods, menopausal syndrome (in combination with oestrogen), or to postpone a period. Norethindrone was the first orally highly active progestin to be synthesized. It was synthesized for the first time by chemists Luis E. Miramontes, Carl Djerassi, and George Rosenkranz at Syntex in Mexico City in 1951.[1] It was the progestin used in one of the first two oral contraceptives. It is often used as the related ester, norethisterone acetate.
References
- ↑ Djerassi C, Miramontes L, Rosenkranz G, Sondheimer F (1954). "Steroids. LIV. Synthesis of 19-Nor-17α-ethynyltestosterone and 19-Nor-17α-methyltestosterone" (abstract page). J Am Chem Soc. 76 (16): 4089&ndash, 4091. doi:10.1021/ja01645a009.
Template:Sex hormones de:Norethisteron Template:WH Template:WS
- Pages with script errors
- CS1 maint: Multiple names: authors list
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Progestagens